The estimated Net Worth of Peter Hug is at least $540 Thousand dollars as of 17 June 2024. Peter Hug owns over 1,193 units of ADC Therapeutics SA stock worth over $536,973 and over the last few years Peter sold ADCT stock worth over $3,448.
Peter has made over 1 trades of the ADC Therapeutics SA stock since 2024, according to the Form 4 filled with the SEC. Most recently Peter sold 1,193 units of ADCT stock worth $3,448 on 17 June 2024.
The largest trade Peter's ever made was selling 1,193 units of ADC Therapeutics SA stock on 17 June 2024 worth over $3,448. On average, Peter trades about 597 units every 0 days since 2024. As of 17 June 2024 Peter still owns at least 182,644 units of ADC Therapeutics SA stock.
You can see the complete history of Peter Hug stock trades at the bottom of the page.
Peter's mailing address filed with the SEC is 430 MOUNTAIN AVENUE, SUITE 404, , NEW PROVIDENCE, NJ, 07974.
Over the last few years, insiders at ADC Therapeutics SA have traded over $225,811 worth of ADC Therapeutics SA stock and bought 800,000 units worth $2,248,000 . The most active insiders traders include Ron Squarer, Victor Sandor, and Group, Llc Green Jeremy Red.... On average, ADC Therapeutics SA executives and independent directors trade stock every 6 days with the average trade being worth of $281,514. The most recent stock trade was executed by Group, Llc Green Jeremy Red... on 1 July 2024, trading 800,000 units of ADCT stock currently worth $2,248,000.
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are ADCT-402, an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and ADCT-301, an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 and ADCT-602, as well as preclinical product candidates, including ADCT-701 and ADCT-901. ADC Therapeutics SA has a collaboration and license agreement with Genmab A/S. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ADC Therapeutics SA executives and other stock owners filed with the SEC include: